Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Member, St. Jude Faculty
Chair, Pharmaceutical Sciences
Pharmaceutical Sciences
Mary Relling, PharmD
Pharmaceutical Sciences
MS313, Room I5112
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: mary.relling@stjude.org
Phone: (901) 595-2348
FAX: (901) 525-8869
BS - University of Arizona
PharmD - University of Utah College of Pharmacy
Improving the drug therapy of childhood leukemia
Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, Neale G, Howard SC, Evans WE, Pui CH, Relling MV. Pharmacokinetic, pharmacodynamic and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood December 10, 2010.
Relling MV, Altman RB, Goetz MP, Evans WE. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol April 20, 2010.
Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Coustan-Smith E, Kun LE, Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML, Boyett JM, Leung W, Handgretinger R, Downing JR, Evans WE, Relling MV. Treatment of childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med Jun 25;360(26):2730-41, 2009.
Trevino LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, Evans WE, Relling MV. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009.
Gu X, Frankowski RF, Rosner GL, Relling MV, Peng B, Amos C. A modified forward multiple regression in high-density genome-wide association studies for complex traits. Genet Epidemiol 2009.
Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui CH, Smith M, Hunger SP, Willman CL, Downing JR; the Children's Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470-80, 2009.
Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 27:2604-14, 2009.
Yang L, Boyd K, Kaste SC, Kamdem LK, Rahija RJ, Relling MV. A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. J Orthop Res 27:169-175, 2008.
Yang J, Cheng C, Yang W, Pei D, Cao X, Fan Y, Pounds S, Trevino L, French D, Campana D, Downing J, Evans WE, Pui C, Devidas M, Bowman W, Camitta B, Willman CL, Davies S, Borowitz M, Carroll WL, Hunger SP, Relling MV. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301:393-403, 2009.
Yang J, Bhojwani D, Yang W, Cai X, Stocco G, Crews K, Wang J, Morrison D, Devidas M, Hunger SP, Willman CL, Raetz EA, Pui C, Evans WE, Relling MV, Carroll WL. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 112:4178-83, 2008.
Yang J, Bogni A, Cheng C, Bleibel WK, Cai X, Fan Y, Yang W, Rocha JC, Pei D, Liu W, Dolan ME, Pui CH, Relling MV. Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia. Clin Pharmacol Ther 84:691-7, 2008.
Bhojwani D, Kang H, Menezes RX, Yang W, Sather H, Moskowitz N, Min DJ, Potter J, Harvey R, Hunger SP, Seibel N, Raetz E, Pieters R, Relling MV, Den Boer ML, Willman CL, Carroll WL. Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children’s Oncology Study: J Clin Oncol 26:4376-84, 2008.
French D, Yang W, Hamilton LH, Neale G, Fan Y, Downing JR, Cox NJ, Pui CH, Evans WE, Relling MV. Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs. PLoS ONE 3:e2144, 2008.
Quintana FA, Muller P, Rosner GL, Relling MV. A semiparametric Bayesian model for repeatedly repeated binary outcomes. J R Stat Soc Ser C Appl Stat 57: 419-431, 2008.
Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, Robinson LL, Sklar CA, Stovall M, Bhatia S. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112:2789-95, 2008.
Mullighan CG, Miller CB, Phillips LA, Radtke I, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR. BCR-ABL 1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453:110-4, 2008.
Davies SM, Borowitz MJ, Rosner GL, Ritz K, Devidas M, Winick N, Martin PL, Bowman P, Elliott J, Willman C, Das S, Cook EH, Relling MV. Pharmacogenetics of minimal residual disease response in children with Acute Lymphoblastic Leukemia (ALL): a report from the Children's Oncology Group. Blood 111:2984-90, 2008.
French D, Hamilton LH, Mattano LA Jr, Sather HN, Devidas M, Nachman JB, Relling MV. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 111:4496-9, 2008.
Hartford C, Vasquez E, Schwab M, Edick MJ, Rehg JE, Grosveld G, Pui CH, Evans WE, Relling MV. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res 67: 4965-72, 2007.
Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I; Pharmacogenetics Research Network. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 81:328-45, 2007.
Jones TS, Yang W, Evans WE, Relling MV. Using HapMap tools in pharmacogenomic discovery: The thiopurine methyltransferase polymorphism. Clin Pharmacol Ther 81:729-34, 2007.
Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff SA, Downing JR. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758-64, 2007.
Hartford C, Yang W, Cheng C, Fan Y, Liu W, Trevino L, Pounds S, Neale G, Raimondi SC, Bogni A, Dolan ME, Pui CH, Relling MV. Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia 21:2128-36, 2007.
Kishi S, Cheng C, French D, Pei D, Das S, Cook EH, Hijiya N, Rizzari C, Rosner GL, Frudakis T, Pui CH, Evans WE, Relling MV. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109:4151-7, 2007.
Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring HZ, Schuldiner AR, Weinshilboum RM, Weiss ST. Pharmacogenomics: challenges and opportunities. Ann Intern Med 145:749-57, 2006.
Bogni A, Cheng C, Liu W, Yang W, Pfeffer J, Mukatira S, French D, Downing JR, Pui CH, Relling MV. Genome wide approach to identify risk factors for therapy-related myeloid leukemia. Leukemia 20:239-246, 2006.
French D, Wilkinson MR, Yang W, de chaisemartin L, Cook EH, Das S, Ratain MJ, Evans WE, Downing JR, Pui CH, Relling MV. Global gene expression as a function of germline genetic variation. Hum Mol Genet 14:1621-1629, 2005.
Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH, Sandlund JT, Rubnitz J, Ribeiro R, Pui CH, Evans WE, Relling MV. Pharmacogenetics of Outcome in Children with Acute Lymphoblastic Leukemia. Blood 105: 4752-4758, 2005.
Edick MJ, Cheng C, Yang W, Cheok M, Wilkinson MR, Deqing P, Evans, WE, Kun LE, Pui CH, Relling MV. Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosomes Cancer 42:107-116, 2005.
Pui CH, Relling MV. Can the genotoxicity of chemotherapy be predicted? Lancet 364:917-918, 2004.
Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ. CYP2B6, CYP3A4 and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos 32:930-936, 2004.
Relling MV, Yang W, Das S, Cook EH, Rosner GL, Neel M, Howard S, Ribeiro R, Sandlund JT, Pui Ch, Kaste SC. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 22:3930-3936, 2004.
Holleman A, Cheok MH, den Boer ML, Yang W, Veerman A, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, Janka-Schaub GE, Pieters R, Evans WE. Gene Expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351:533-542, 2004.
Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468, 2004.
Pui CH, Relling MV, Downing JR. Acute Lymphoblastic leukemia. N Engl J Med 350:1535-1548, 2004.
Blanco JG, Edick MJ, Relling MV. Etoposide induces chimeric Mll gene fusions. FASEB J 18:173-175, 2004.
Pui CH, Sandlund JT, Pei D, Rivera GK, Howard SC, Ribeiro RC, Rubnitz JE, Razzouk BI, Hudson MM, Cheng C, Raimondi, SC, Behm FG, Downing JR, Relling MV, Evans WE. Results of therapy for acute lymphoblastic leukemia in black and white children. J Am Med Assoc 290:2001-2007, 2003.
Cheok MH, Yang W, Pui CH, Downing JR, Cheng C, Naeve CW, Relling MV, Evans WE, Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 34: 85-90, 2003.
Relling MV, Boyett JM, Blanco JG, Raimondi S, Behm FG, Sandlund JT, Rivera GK, Kun LE, Evans WE, Pui C-H. Granulocyte-colony stimulating factor and the risk of secondary myeloid malignancy after etoposide. Blood 101:3862-3867, 2003.
Yeoh EJ, Ross ME, Shurtleff S, Williams K, Patel DH, Raimondi S, Behm FG, Relling MV, Patel A, Cheng C, Campana D, Wilkins S, Zhou X, Li J, Liu H, Pui C-H, Evans WE, Naeve CW, Wong L, Downing JR. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133-143, 2002.
Blanco JG, Dervieux T, Edick M, Mehta PK, Rubnitz JE, Shurtleff S, Raimondi SC, Behm FG, Pui CH, Relling MV. Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci USA 98:10338-10343, 2001.
Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nature Rev Cancer 1:99-108, 2001.
Ratain MJ, Relling MV. Gazing into a crystal ball - cancer therapy in the post-genomic era. Nat Med 7:285-287, 2001.
Relling MV, Pui C-H, Sandlund JT, Rivera GK, Hancock ML, Boyett JB, Evans WE. Chronic anticonvulsant therapy reduces the efficacy of chemotherapy for childhood acute lymphoblastic leukemia. Lancet 356:285-290, 2000.
Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001-2008, 1999.
Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491, 1999.
Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, Kun LE, Walter AW, Evans WE, Pui C-H. High incidence of secondary brain tumors related to irradiation and antimetabolite therapy. Lancet 354:34-39, 1999.
Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui C-H. Conventional versus individualized doses of chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505, 1998.
Evans WE, Relling MV. Clinical pharmacodynamics of antineoplastics agents in humans. Clin Pharmacokinet 16:327-336, 1989.
Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behm FG, Pui C-H. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 12:346-352, 1998.
Chen C-L, Fuscoe JC, Liu, Q, Pui C-H, Mahmoud H, Relling MV. Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J Natl Cancer Inst 88:1840-1847, 1996.
Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR. O-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 45:352-358, 1994.
Last update: December 2010
